Targeting mPEG-poly (lactide-co-glycplide) drug-loaded nano-micelles inhibit liver cancer.

Article Tools Tumor Biology Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/jco.2014.32.15_suppl.e22144 Journal of Clinical Oncology - published online before print May 20, 2014 Targeting mPEG-poly (lactide-co-glycplide) drug-loaded nano-micelles inhibit liver cancer. Chang ShuxChang ShuSearch for articles by this author , Peng XuxPeng XuSearch for articles by this author , Xin YuexXin YueSearch for articles by this author , Tiancheng LuxTiancheng LuSearch for articles by this author , Chun WangxChun WangSearch for articles by this author , Long LinxLong LinSearch for articles by this author , Xiaoyi XuxXiaoyi XuSearch for articles by this author Show More Department of Obstetrics, First Hospital of Jilin University, Changchun, China; First Hospital of Jilin University, Changchun, China; 208 Hospital PLA, Changchun, China; College of Life Sciences, Jilin Agricultural University, Changchun, China; Departments of Intervention, Jilin Province Tumor Hospital, Changchun, China; Changchun City Central Hospital, Changchun, China Abstract Disclosures https://doi.org/10.1200/jco.2014.32.15_suppl.e22144 Abstract Abstract e22144 Background: To improve targeting and to reduce the side effects of drugs is the key to improve the efficacy of chemotherapy. "Polymer micelle drug" is the hot topic in the field of anticancer drugs in recent years. Methods: Based on the understanding of the liver reticuloendothelial system (RES), the principle of tumor EPR passive targeting effect, the selective uptake of the organ, and active targeting, the present paper reports a novel smart drug delivery system (DDS), designs and prepares Doxorubicin-conjugates and in situ liver cancer animal models. In order to compare the partitions of the nano-micelles in the cancerous tissue and in the healthy part of the liver due to the RES capture and the EPR effect, the novel predrug composes of various targeting molecules, such as folic acid, tripeptide arginine-glycine-aspartic acid (RGD) and lactose, which overexpress in the vascular endothelial cells and epithelial solid carcinoma, or liver tumor cells. Results: This DDS has a satisfactory drug loading capacity (19.0-26.6 wt/wt.%). Moreover, the efficacy and safety of the system evaluated systematically. When this DDS was applied to inhibit tumors in vivo, it presented a tumor tissue aggregation and enrichment compared to healthy tissue due to nano-micelles. Furthermore, experimental data demonstrated stronger anti-tumor abilities compared to the targeting-free micelles. Conclusions: This DDS may be a new candidate for the targeting treatment of various solid cancers. In other words, the results of this work will lead to not only establishment of the improved liver-cancer-targeting nano-micellular drug delivery system, but also new knowledge of utilizing the advantages of the both passive targeting and active targeting and avoiding mutual cancelling of them. This is beneficial for investigation of anti-hepatitis drugs and other targeted drug delivery systems and for development of the polymer-conjugate pharmacology. © 2014 by American Society of Clinical Oncology